Hôpital Claude Huriez

Running trials

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers

  NCT06958224· University Hospital, Lille· Source

• Recruiting

  Momelotinib in VEXAS Syndrome

  NCT07098936· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Not yet recruiting

  Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus

  NCT06356740· Phase 2· Hospices Civils de Lyon· Source

• Not yet recruiting

  Hodgkin's Disease and Chemotherapy Before 40 Years

  NCT06116929· Lille Catholic University· Source

• Active, not recruiting

  Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06029972· Phase 2· Gilead Sciences· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Recruiting

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

  NCT05689151· Pfizer· Source

• Recruiting

  Cost-utility of Focal HIFU vs Prostatectomy

  NCT05710861· University Hospital, Bordeaux· Source

• Recruiting

  Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot

  NCT05491577· Centre Hospitalier Universitaire de Nīmes· Source

• Recruiting

  A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  NCT04988555· Phase 1/2· Sumitomo Pharma America, Inc.· Source

• Recruiting

  Evaluation of Long-term Adverse Effects of Gastric Bypass in Omega

  NCT04930029· University Hospital, Lille· Source

• Active, not recruiting

  The CROCO Study: CROhn's Disease COhort Study

  NCT05420233· GLSMED Learning Health S.A.· Source

• Recruiting

  National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

  NCT04166266· ANRS, Emerging Infectious Diseases· Source

• Active, not recruiting

  Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

  NCT04144387· Intergroupe Francophone du Myelome· Source

• Active, not recruiting

  An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

  NCT03606577· Phase 2· Nantes University Hospital· Source

• Active, not recruiting

  9-ING-41 in Patients With Advanced Cancers

  NCT03678883· Phase 2· Actuate Therapeutics Inc.· Source

• Recruiting

  A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

  NCT03472157· University Hospital, Lille· Source

• Active, not recruiting

  Impact of Weight Loss Induced by Bariatric Surgery or Nutritional Management on Sexual Function in Men With Severe Obesity

  NCT03528980· University Hospital, Lille· Source

• Active, not recruiting

  Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

  NCT01376752· Phase 3· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Childhood cancers1 recruiting
• Diabetic foot ulcer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

  NCT05529524· The Lymphoma Academic Research Organisation· Source

• Completed

  Partial Nephrectomy in Low Pressure

  NCT05404685· University Hospital, Bordeaux· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Swedish Orphan Biovitrum· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Takeda· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

  NCT04785820· Phase 2· Hoffmann-La Roche· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Bayer· Source

• Completed

  Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

  NCT04424303· Pfizer· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

  NCT03635983· Phase 3· Bristol-Myers Squibb· Source

• Completed

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· Phase 1· Hoffmann-La Roche· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source

• Completed

  Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

  NCT03246516· University Hospital, Lille· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· University Hospital, Essen· Source

• Terminated

  A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

  NCT02841540· Phase 1· Hemavant Sciences GmbH· Source

• Completed

  French Registry of First-line Treatment of Acute Promyelocytic Leukemia

  NCT02938858· Groupe Francophone des Myelodysplasies· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Bladder cancer28 works · 0 trials
• Follicular lymphoma6 works · 1 trial
• Hyperparathyroidism6 works · 0 trials